Alector (ALEC) Q3 2026 earnings review
Alector's cash lasts into 2029, but GSK ends their partnership
Alector, a brain-disease drug developer, lost GSK as a partner but signed a deal with Genentech. Its $125 million profit came from accounting: GSK's exit let Alector book the rest of old GSK payments as revenue. Without that and a license fee, the quarter's loss was about $23 million. Chief executive Arnon Rosenthal said Alector "strengthened our balance sheet".
| Revenue | $162.9M $3.3M a year ago; all a one-time release of old GSK payments |
|---|---|
| Loss excluding one-offs | $22.8M $23.0M loss last quarter |
| Cash and investments, Sept 30 | $138.7M about $299M with the Genentech payment and share sale, by our math |
| Cash outlook | Extended into the second half of 2029; was through 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better, because Alector's cash now lasts into the second half of 2029, not just through 2027. Genentech's payment, a share sale and lower costs did that. One caution: each existing share owns a smaller part of the company, and the lead Alzheimer's drug's US filing moved later.
The question now is whether AL137, the lead Alzheimer's drug, avoids the blood side effects of similar brain-entry drugs. A clean record would support every Alector drug; blood problems would leave Genentech's milestones as the main hope. Safety data from the first doses, planned by April 2027, will tell.
🐂 Bull Case
Genentech Pays $100 Million for a Parkinson's Drug
Alector licensed AL050 to Genentech, part of the Roche group, on the last day of the quarter. AL050 is an engineered form of GCase, an enzyme that some Parkinson's patients lack. Its delivery relies on the Alector Brain Carrier (ABC), the company's technology for moving drugs from the blood into the brain.
Genentech paid $100 million upfront and takes over development, manufacturing and sales. Alector can also earn up to $1.17 billion in milestone payments, plus royalties on sales. The deal leaves ABC with Alector for its own drugs outside this enzyme.
The deal matters because a large drug maker paid cash for a drug built on ABC, the technology behind every Alector program. But Alector paid Spur Therapeutics $15 million for an enzyme patent license, and owes Spur a share "in the teens" of future milestones. By our math, that leaves Alector $85 million of the upfront payment.
What to watch: the first milestone payment, which Alector says "may never occur" because Genentech now controls the work. A payment would show Genentech pushing AL050 toward human trials on its own money.
Cash Now Covers Spending Into 2029
Alector, which has no drug on sale, pays for its research with cash from partners and share sales. Three months ago it said its money would last at least through 2027. Now the drug developer says its cash covers operations into the second half of 2029.
Three moves did it. The Genentech payment and a share sale that raised about $75 million before fees added cash. Spending also fell: excluding the Spur fee, operating costs dropped 42% from a year ago, after Alector laid off much of its staff last October.
What to watch: quarterly spending once AL137 enters human trials in 2027. Alector still writes that it "will need to obtain substantial additional funding in the future", and faster spending would bring that need closer.
🐻 Bear Case
The Profit Came From GSK Leaving
Alector reported net income of $124.6 million, after a loss a year earlier. The profit did not bring in any new cash. GSK, its partner on two brain drugs that failed in trials, gave notice on July 6 that it would end their collaboration.
The deal's end removed Alector's remaining development work for GSK. So Alector booked the last $162.9 million of GSK's old upfront payments as revenue, all at once. Its quarterly filing says it does "not expect to derive further revenue from the GSK Agreement".
- Loss excluding the GSK release and the Spur license fee: about $22.8 million, by our math
- Loss last quarter: $23.0 million
This matters because GSK money funded Alector for five years. Future revenue now rests on Genentech, and Alector says those milestones depend on work outside its control.
What to watch: the loss excluding one-offs next quarter. Alector will book the Genentech payment as revenue once it transfers the license, so another one-time profit could appear. Only the underlying loss will show what running the company costs.
Share Sale Grows Share Count by a Third
Alector said it sold new shares in October "priced at a premium to market", meaning above the previous day's closing price. The sale added 36.6 million shares to the 112.3 million outstanding at the end of September.
By our math, the share count rises about 33%, so existing owners gave up about a quarter of their claim on the company. The board also lowered the price at which staff can buy shares under about 4.1 million options, to below the sale price.
What to watch: sales through Alector's $125 million at-the-market program, which lets it sell shares on the exchange in small amounts. Any use before the first AL137 data would shrink existing owners' part again.
Lead Drug's US Filing Moves Back Again
AL137 is Alector's lead Alzheimer's drug, an antibody against a form of amyloid found in brain plaques. Studies in patients need a US investigational new drug application (IND), the filing that lets a company start US trials. Alector has moved its target for that filing back three times.
- Target set in November 2025: during 2026
- Target set in early 2026: late 2026 or early 2027
- Target last quarter: first quarter of 2027
- Target now: second quarter of 2027
Chief executive Arnon Rosenthal said Alector is "advancing toward multiple clinical readouts". But each delay pushes back the first data in Alzheimer's patients, and Alector gave no reason for the latest one.
What to watch: whether the US filing arrives by the end of June 2027. Meeting that date would keep the first study in Alzheimer's patients on the current plan.
👓 Other Themes
Alector Paid Off Its Hercules Loan
On July 8, Alector repaid its loan from Hercules Capital and ended the agreement. It paid $10.4 million in principal, interest and early-repayment charges. With no debt left, the Genentech money and the share proceeds can go to research instead of lenders.
💲 Other KPIs
Overhead costs, the pay and fees for executive, legal and finance work, fell 22% from a year ago to $9.0 million. Fewer staff after the layoffs drove the drop. These costs have stayed between $8.1 million and $9.0 million for three quarters, so the savings have levelled off.
Interest and other income fell 72% from a year ago, to $0.8 million. Alector held fewer investments, and paying off its loan early added a $0.6 million loss. Excluding that loss, the decline was about 52% by our math. The Genentech cash and the share proceeds arrived after the quarter ended.
Shareholders' equity, the book value left for owners after all liabilities, swung from a $10.0 million deficit in June to $116.6 million. The release of GSK deferred revenue drove the change, not new cash. The October share sale will lift it again in the fourth quarter.
🔮 Guidance
Raised. Alector now expects its cash to fund operations into the second half of 2029, against at least through 2027 before. The plan includes the Genentech payment, net of the Spur fee, and the October share sale. By our math, the period the cash covers grew from about 18 months to at least 33. Alector still writes that it will need more funding later.
Unchanged. Alector still plans the first human doses of AL137, in healthy volunteers in Australia, no later than April 2027. It submitted the registration with an Australian ethics committee in October. The doses go under the skin, the monthly route Alector chose for the drug.
Delayed. Alector now targets the second quarter of 2027 for the US filing that would let it test AL137 in Alzheimer's patients. Last quarter the target was the first quarter of 2027. The move pushes the first patient study back by about three months.
New. Alector plans first human studies in the second quarter of 2028 for AL164, its tau-lowering drug for Alzheimer's, and AL062, its alpha-synuclein drug for Parkinson's. Both are siRNA medicines, which silence the gene that makes a harmful protein. Patients would receive them by injection under the skin.
❓ Key Questions
When will Genentech's $100 million count as revenue?
Alector books the payment once it transfers the license and know-how. If that happens in the fourth quarter, reported profit will again come from a one-time item, and the underlying loss will matter more.
Why did the AL137 US filing move later?
The target moved from the first to the second quarter of 2027 without an explanation. The first study in Alzheimer's patients depends on that filing, so the cause of the delay matters.
How much will spending rise once human trials start?
Underlying costs sit near their lowest level after the layoffs. The cash outlook into 2029 rests on Alector's current operating plan, but it has not said what the AL137, AL164 and AL062 trials will cost.
Will Alector sell shares through its $125 million program?
Alector has not used the at-the-market program it set up in May, which lets it sell shares on the exchange. Any sales would add to the share count that the October sale already lifted.
What happens to AL050's planned 2027 US filing?
Alector had targeted a 2027 US filing for AL050. Genentech now runs the program and the release gives no date, so the timing of a first milestone payment is unclear.